Is Amarantus BioScience Holdings, Inc. (AMBS) a Buy, Sell, or Hold?
OTC : AMBS
Amarantus BioScience Holdings, Inc.
$0.0001 USD
$0 (0.0%)
- Volume
- 7.02K
- Average Volume
- 10.64K
- Market Capitalization
- $36.84K
- P/E Ratio
- -0.01
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.00
Company Overview
OTC
John Wesley Commissiong
Biotechnology
Healthcare
AMBS
12
US
USD
Liquidity Metrics
-0.78
0.00
0.00
0.00
0.00
Sales & Valuation
$95331
0.39
0.00
-0.01
-0.01
Profitability
-$0.0082
-$4.76M
-4995.23%
-4995.23%
21.36%
-46.65%
P/E Metrics
-0.01
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Poll Results
About Amarantus BioScience Holdings, Inc. (OTC:AMBS) Stock
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are ... developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Frequently Asked Questions
-
What is the current Amarantus BioScience Holdings, Inc. (AMBS) stock price?
-
Amarantus BioScience Holdings, Inc.(OTC:AMBS) stock price is $0.0001 in the last trading session. During the trading session, AMBS stock reached the peak price of $0.0003 while $0.00001 was the lowest point it dropped to. The percentage change in AMBS stock occurred in the recent session was 0.0% while the dollar amount for the price change in AMBS stock was $0.
-
AMBS's industry and sector of operation?
-
The OTC listed AMBS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AMBS?
-
Robert Lewis Harris | Compliance Officer & Director
Ravi Kiron | Senior Vice President of Business Development
Brian E. Harvey | Chief Regulatory Advisor & Member of Board of Advisors
Aimee Boutcher | Director of Investor Relations
Owen Garrick | Corporate Advisor -
How many employees does AMBS have?
-
Number of AMBS employees currently stands at 12. AMBS operates from 45 Wall Street, New York City, NY 10005, US.
-
Link for AMBS official website?
-
Official Website of AMBS is: https://www.amarantus.com
-
How do I contact AMBS?
-
AMBS could be contacted at phone #650-862-5391 and can also be accessed through its website. AMBS operates from 45 Wall Street, New York City, NY 10005, US.
-
How many shares of AMBS are traded daily?
-
The average number of AMBS shares traded daily for last 3 months was 10.64K.
-
What is the market cap of AMBS currently?
-
The market value of AMBS currently stands at $36.84K with its latest stock price at $0.0001